Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its Category 1 product candidate, ZG2001.
ZG2001: An Oral Pan-KRAS Mutation Inhibitor
ZG2001, an in-house developed oral pan-KRAS mutation inhibitor, is under development for the treatment of KRAS mutant tumors. This molecule has demonstrated promising anti-tumor effects in both in vivo and in vitro tests, indicating its potential efficacy in combating KRAS-driven cancers.
Synergistic Anti-Tumor Effects and Combination Therapy Potential
ZG2001 has shown significant synergistic anti-tumor effects when combined with KRAS G12C, MEK, and other inhibitors. This suggests that ZG2001 could be a valuable addition to combination therapies, enhancing the treatment options for patients with KRAS mutant tumors.-Fineline Info & Tech
